Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13;111(4):823-825.
doi: 10.4269/ajtmh.24-0171. Print 2024 Oct 2.

Concordance between a New Rapid Point-Of-Care Assay and Standard ELISA in the Detection of Cysticercosis Antigens in Urine

Affiliations

Concordance between a New Rapid Point-Of-Care Assay and Standard ELISA in the Detection of Cysticercosis Antigens in Urine

Luz M Toribio et al. Am J Trop Med Hyg. .

Abstract

Neurocysticercosis is a parasitic disease of major public health importance. Definitive diagnosis requires neuroimaging, which is typically unavailable in rural impoverished regions of endemicity. Screening immunoassays can support diagnosis in this setting by identifying individuals most likely to have severe forms of disease for referral to imaging. Urine sampling is convenient, painless, and generally well accepted. We developed a rapid point-of-care (POC) assay to detect urinary antigens and assessed concordance with a standard antigen ELISA (Ag-ELISA), both using monoclonal antibodies TsW8/TsW5. From 28,145 stored community samples with Ag-ELISA results, we selected 843 for comparison, 281 each from nonreactive (ratio <1), reactive-below-cutoff (ratio 1:3), and positive (ratio ≥3) samples. Overall agreement was 73.6%, with strong agreement observed in the nonreactive (280/281, 99.6%) and positive (255/281, 90.8%) groups. This affordable noninvasive POC test can be applied to identify individuals in the community most at risk of developing severe disease.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Both the parent study and the current study were approved by the institutional review board of the Universidad Peruana Cayetano Heredia (#161-14-23).

Similar articles

References

    1. Cárdenas G, Salgado P, Laura-Foronda E, Popoca-Rodriguez I, Delgado-Hernández RD, Rojas R, Palacios E, 2021. Neglected and (re-)emergent infections of the CNS in low-/middle-income countries. Infez Med 29: 513–525. - PMC - PubMed
    1. Butala C, Brook TM, Majekodunmi AO, Welburn SC, 2021. Neurocysticercosis: Current perspectives on diagnosis and management. Front Vet Sci 8: 615703. - PMC - PubMed
    1. Hamamoto Filho PT, Rodríguez-Rivas R, Fleury A, 2022. Neurocysticercosis: A review into treatment options, indications, and their efficacy. Res Rep Trop Med 13: 67–79. - PMC - PubMed
    1. Dixon MA, Winskill P, Harrison WE, Basáñez MG, 2021. Taenia solium taeniasis/cysticercosis: From parasite biology and immunology to diagnosis and control. Adv Parasitol 112: 133–217. - PubMed
    1. Gabriël S, Blocher J, Dorny P, Abatih EN, Schmutzhard E, Ombay M, Mathias B, Winkler AS, 2012. Added value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings. PLoS Negl Trop Dis 6: e1851. - PMC - PubMed

Substances

LinkOut - more resources